Sign Out
Treatment of relapsing multiple sclerosis.
In clinical trials, this was characterised by ≥2 acute exacerbations in the previous 2 years (see Pharmacology under Actions).
Rebif is not indicated in secondary progressive multiple sclerosis patients who no longer experience relapses.
